Mangoceuticals, Inc. (MGRX) stock
MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
$0.15−0.01 (-8.44%)
Close on Nov 18, 2026Market cap $3.16MP/E –Yield –
Mangoceuticals net income
Net income is the profit left for shareholders after every expense, interest and tax.
Mangoceuticals's net income for the twelve months ending Jun 30, 2026 was -$15.10M. For fiscal 2025 it was -$20.64M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$20.64M | – |
| FY2024 | Dec 31, 2024 | -$8.71M | – |
| FY2023 | Dec 31, 2023 | -$9.21M | – |
| FY2022 | Dec 31, 2022 | -$2.00M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.31M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.40M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.62M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.84M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.95M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.37M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.57M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.28M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$673.66K | – |
| Q3 FY2022 | Sep 30, 2022 | -$994.92K | – |
| Q2 FY2022 | Jun 30, 2022 | -$310.19K | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.60K | – |
See a number that looks wrong?